In October, we reported on a growing number of IPR challenges to Genentech’s U.S. Patent No. 6,407,213 (“the ʼ213 patent”) to...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK]
BiosimilarsIP.com Legal provides analysis of legal decisions from federal courts and from the PTAB related to biologics and biosimilars.
-
-
Last week, the Federal Circuit affirmed a lower court’s dismissal of AbbVie’s complaint seeking declaratory judgment of invalidity of...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
On February 2, 2018, U.S. District Judge George H. Wu granted Genentech’s motion to dismiss a complaint brought by Amgen in the Central...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
This is our second update on the litigation (you can see the prior analyses here and here, in addition to a parallel post on our companion...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
On December 20, 2017, Bristol Myers Squibb Company, Bavarian Nordic, and Enzo Biochem, Inc. filed an amicus brief in support of Amgen’s...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
On December 5, 2017, the Federal Circuit held oral argument in Momenta Pharmaceuticals, Inc. v. Bristol-Myers Squibb Company, 17-1694. The...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
On December 14, 2017, the Federal Circuit issued an opinion in Amgen v. Sandoz, holding that the Biologics Price Competition and Innovation...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK]